Please Wait.....
Report
Neoantigen Targeted Therapies Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Target Disease Indication (Bone Cancer, Colorectal Cancer, Gynecological Cancer, Non-Small Cell Lung Cancer, Renal Cell Carcinoma), By Neoantigens Type (Off-the-Shelf Neoantigens, Personalized Neoantigens), By Immunotherapy Type (Dendritic Cell Vaccines, DNA / RNA-Based Vaccines, Protein / Peptide-based Vaccines, TIL-Based Therapies), By Route of Administration (Intradermal, Intravenous, Subcutaneous), By Region & Competition, 2020-2030F
Market Report I 2025-03-24 I 182 Pages I TechSci Research
Global Neoantigen Targeted Therapies Market was valued at USD 1.88 billion in 2024 and is anticipated to witness an impressive growth in the forecast period with a CAGR of 8.34% through 2030. Neoantigen Targeted Therapies are a cutting-edge approach in cancer treatment that harnesses the power of the immune system to specifically recognize and attack cancer cells. These therapies are designed to target neoantigens, which are unique protein fragments found on the surface of cancer cells because of mutations in the tumor's DNA. For instance, according to a study published by the Indian Journal of Medical Research in December 2022, the estimated number of new cancer cases in India for 2022 was 14,61,427. The report highlights the growing cancer burden in the country, emphasizing the need for enhanced awareness, early detection, and improved treatment strategies to address the rising incidence. Neoantigens are distinct from normal, healthy cell proteins, making them ideal targets for immune recognition and attack. Neoantigen therapies are highly personalized. Once neoantigens are identified, the patient's immune system is trained to recognize these specific neoantigens as foreign invaders. This often involves creating a customized vaccine or adoptive cell therapy tailored to the patient's unique neoantigen profile. Neoantigen therapies can be used in combination with checkpoint inhibitors, another type of immunotherapy. Checkpoint inhibitors release the brakes on the immune system, allowing it to mount a stronger response against cancer cells, including those targeted by neoantigens.
The growing availability and affordability of genomic sequencing technologies have enabled the identification of neoantigens more accurately and quickly, facilitating the development of personalized therapies. Regulatory agencies like the FDA and EMA have shown willingness to support the development and approval of neoantigen therapies, streamlining the path to market for these treatments. Patients and healthcare providers are increasingly seeking precision therapies that specifically target cancer cells. Neoantigen therapies offer the potential for more effective and less toxic treatments. Researchers are exploring the synergistic effects of combining neoantigen therapies with other treatment modalities, such as chemotherapy and radiation therapy, to enhance treatment outcomes. The aging population is at higher risk of developing cancer. As the global population ages, the demand for innovative cancer treatments, including neoantigen therapies, is expected to rise.
Key Market Drivers
Advancements in Genomic Testing
Next-generation sequencing technologies have revolutionized the field of genomics. NGS allows for the rapid and cost-effective sequencing of large stretches of DNA. It has enabled the sequencing of entire genomes, transcriptomes, and epigenomes with unprecedented speed and affordability. For instance, a study published in PNAS in September 2022 reported that researchers developed an antibody-based therapy that successfully eliminated circulating tumor cells (CTCs) in breast cancer mouse models. This breakthrough highlights the potential of targeted immunotherapy in preventing cancer metastasis, offering hope for improved treatment strategies and better outcomes for breast cancer patients in the future. High-throughput sequencing platforms can simultaneously process numerous DNA or RNA samples, allowing for large-scale studies and population-scale genomic research. This capability has accelerated the discovery of genetic variants associated with diseases and traits. Traditional short-read sequencing methods have limitations in resolving complex genomic regions. Long-read sequencing technologies, like Pacific Biosciences (PacBio) and Oxford Nanopore, can generate much longer sequencing reads, aiding in the assembly of complete genomes and the identification of structural variations. Single-cell sequencing technologies enable the analysis of individual cells within a tissue or organism. This approach provides insights into cellular heterogeneity, cell types, and gene expression at a single-cell resolution, advancing our understanding of complex biological systems. Genomic sequencing has been instrumental in cancer research and precision oncology. It allows for the identification of driver mutations, assessment of tumor heterogeneity, and the development of targeted therapies tailored to a patient's genetic profile.
Key Market Challenges
Identification of Relevant Neoantigens
Tumors are often genetically heterogeneous, meaning they contain a mix of different cell types with various mutations. Identifying the specific neoantigens that are present across all tumor cells can be challenging. Neoantigen prediction relies on computational algorithms to predict potential neoantigens based on DNA sequencing data. These algorithms are continually improving, but false positives and false negatives are still common, leading to uncertainty in selecting the most relevant neoantigens. Predicted neoantigens must be experimentally validated to confirm their presentation on cancer cells and their immunogenicity. This validation process can be time-consuming and resource intensive. Each patient's tumor has a unique set of neoantigens, and these can vary greatly from one patient to another. Identifying relevant neoantigens requires a personalized approach for each patient, which can be logistically challenging. Some neoantigens may be present at very low frequencies within a tumor, making them difficult to detect and target effectively. Tumors can evolve over time, leading to changes in their neoantigen landscape. This requires ongoing monitoring and adaptation of neoantigen-targeted therapies. Cancer cells may develop mechanisms to evade the immune system, including downregulating the presentation of neoantigens. This immune evasion can hinder the effectiveness of neoantigen-targeted therapies.
Key Market Trends
Immunotherapy Dominance
Immunotherapy has gained prominence as a leading approach in cancer treatment. It harnesses the body's immune system to target and destroy cancer cells. Neoantigen-targeted therapies are a subset of immunotherapy that focuses on training the immune system to recognize and attack cancer-specific neoantigens. Immunotherapy, including neoantigen-targeted therapies, aligns with the principles of precision medicine. These therapies are tailored to the individual genetic and immunological profiles of each patient, aiming to maximize treatment efficacy while minimizing side effects. Neoantigen-targeted therapies often complement the use of checkpoint inhibitors, another class of immunotherapies. Checkpoint inhibitors release the brakes on the immune system, allowing it to attack cancer cells more effectively. Neoantigens can serve as specific targets for the immune system to recognize in combination with checkpoint inhibitors. Neoantigen-targeted therapies aim to enhance the immune system's response against cancer cells by targeting neoantigens, which are unique to the tumor. This can lead to a more focused and potent immune response compared to traditional treatments. Positive outcomes and clinical successes in immunotherapy trials, including neoantigen therapies, have fueled interest and investment in this field. Patients who have experienced durable responses are advocating for and raising awareness of these treatments. The pharmaceutical and biotechnology industries have invested heavily in the research and development of immunotherapies, including neoantigen-based approaches. This investment has led to a growing pipeline of potential therapies.
Key Market Players
- BioNtech SE
- Gritstone Bio, Inc.
- Genocea Biosciences Inc.
- Moderna Inc
- Agenus Inc.
- Immatics NV
- Advaxis Inc
- Precision Biologics
- Gilead Sciences, Inc.
- Cellular Biomedicine Group Inc.
- Achillies Therapeutics Plc.
- Merck & Co Inc
Report Scope:
In this report, the Global Neoantigen Targeted Therapies Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
- Neoantigen Targeted Therapies Market, By Target Disease Indication:
o Bone Cancer
o Colorectal Cancer
o Gynecological Cancer
o Non-Small Cell Lung Cancer
o Renal Cell Carcinoma
- Neoantigen Targeted Therapies Market, By Neoantigens Type:
o Off-the-Shelf Neoantigens
o Personalized Neoantigens
- Neoantigen Targeted Therapies Market, By Immunotherapy Type:
o Dendritic Cell Vaccines
o DNA / RNA-Based Vaccines
o Protein / Peptide-based Vaccines
o TIL-Based Therapies
- Neoantigen Targeted Therapies Market, By Route of Administration:
o Intradermal
o Intravenous
o Subcutaneous
- Neoantigen Targeted Therapies Market, By region:
o North America
United States
Canada
Mexico
o Asia-Pacific
China
India
South Korea
Australia
Japan
o Europe
Germany
France
United Kingdom
Spain
Italy
o South America
Brazil
Argentina
Colombia
o Middle East & Africa
South Africa
Saudi Arabia
UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Neoantigen Targeted Therapies Market.
Available Customizations:
Global Neoantigen Targeted Therapies Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to five).
1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Applications
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Impact of COVID-19 on Global Neoantigen Targeted Therapies Market
5. Voice of Customer
6. Global Neoantigen Targeted Therapies Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Target Disease Indication (Bone Cancer, Colorectal Cancer, Gynecological Cancer, Non-Small Cell Lung Cancer, Renal Cell Carcinoma)
6.2.2. By Neoantigens Type (Off-the-Shelf Neoantigens, Personalized Neoantigens)
6.2.3. By Route of Administration (Intradermal, Intravenous, Subcutaneous)
6.2.4. By Immunotherapy Type (Dendritic Cell Vaccines, DNA / RNA-Based Vaccines, Protein / Peptide-based Vaccines, TIL-Based Therapies)
6.2.5. By Region
6.2.6. By Company (2024)
6.3. Market Map
7. Asia Pacific Neoantigen Targeted Therapies Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Target Disease Indication
7.2.2. By Neoantigens Type
7.2.3. By Route of Administration
7.2.4. By Immunotherapy Type
7.2.5. By Country
7.3. Asia Pacific: Country Analysis
7.3.1. China Neoantigen Targeted Therapies Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Target Disease Indication
7.3.1.2.2. By Neoantigens Type
7.3.1.2.3. By Route of Administration
7.3.1.2.4. By Immunotherapy Type
7.3.2. India Neoantigen Targeted Therapies Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Target Disease Indication
7.3.2.2.2. By Neoantigens Type
7.3.2.2.3. By Route of Administration
7.3.2.2.4. By Immunotherapy Type
7.3.3. Australia Neoantigen Targeted Therapies Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Target Disease Indication
7.3.3.2.2. By Neoantigens Type
7.3.3.2.3. By Route of Administration
7.3.3.2.4. By Immunotherapy Type
7.3.4. Japan Neoantigen Targeted Therapies Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Target Disease Indication
7.3.4.2.2. By Neoantigens Type
7.3.4.2.3. By Route of Administration
7.3.4.2.4. By Immunotherapy Type
7.3.5. South Korea Neoantigen Targeted Therapies Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Target Disease Indication
7.3.5.2.2. By Neoantigens Type
7.3.5.2.3. By Route of Administration
7.3.5.2.4. By Immunotherapy Type
8. Europe Neoantigen Targeted Therapies Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Target Disease Indication
8.2.2. By Neoantigens Type
8.2.3. By Route of Administration
8.2.4. By Immunotherapy Type
8.2.5. By Country
8.3. Europe: Country Analysis
8.3.1. France Neoantigen Targeted Therapies Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Target Disease Indication
8.3.1.2.2. By Neoantigens Type
8.3.1.2.3. By Route of Administration
8.3.1.2.4. By Immunotherapy Type
8.3.2. Germany Neoantigen Targeted Therapies Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Target Disease Indication
8.3.2.2.2. By Neoantigens Type
8.3.2.2.3. By Route of Administration
8.3.2.2.4. By Immunotherapy Type
8.3.3. Spain Neoantigen Targeted Therapies Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Target Disease Indication
8.3.3.2.2. By Neoantigens Type
8.3.3.2.3. By Route of Administration
8.3.3.2.4. By Immunotherapy Type
8.3.4. Italy Neoantigen Targeted Therapies Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Target Disease Indication
8.3.4.2.2. By Neoantigens Type
8.3.4.2.3. By Route of Administration
8.3.4.2.4. By Immunotherapy Type
8.3.5. United Kingdom Neoantigen Targeted Therapies Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Target Disease Indication
8.3.5.2.2. By Neoantigens Type
8.3.5.2.3. By Route of Administration
8.3.5.2.4. By Immunotherapy Type
9. North America Neoantigen Targeted Therapies Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Target Disease Indication
9.2.2. By Neoantigens Type
9.2.3. By Route of Administration
9.2.4. By Immunotherapy Type
9.2.5. By Country
9.3. North America: Country Analysis
9.3.1. United States Neoantigen Targeted Therapies Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Target Disease Indication
9.3.1.2.2. By Neoantigens Type
9.3.1.2.3. By Route of Administration
9.3.1.2.4. By Immunotherapy Type
9.3.2. Mexico Neoantigen Targeted Therapies Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Target Disease Indication
9.3.2.2.2. By Neoantigens Type
9.3.2.2.3. By Route of Administration
9.3.2.2.4. By Immunotherapy Type
9.3.3. Canada Neoantigen Targeted Therapies Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Target Disease Indication
9.3.3.2.2. By Neoantigens Type
9.3.3.2.3. By Route of Administration
9.3.3.2.4. By Immunotherapy Type
10. South America Neoantigen Targeted Therapies Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Target Disease Indication
10.2.2. By Neoantigens Type
10.2.3. By Route of Administration
10.2.4. By Immunotherapy Type
10.2.5. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Neoantigen Targeted Therapies Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Target Disease Indication
10.3.1.2.2. By Neoantigens Type
10.3.1.2.3. By Route of Administration
10.3.1.2.4. By Immunotherapy Type
10.3.2. Argentina Neoantigen Targeted Therapies Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Target Disease Indication
10.3.2.2.2. By Neoantigens Type
10.3.2.2.3. By Route of Administration
10.3.2.2.4. By Immunotherapy Type
10.3.3. Colombia Neoantigen Targeted Therapies Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Target Disease Indication
10.3.3.2.2. By Neoantigens Type
10.3.3.2.3. By Route of Administration
10.3.3.2.4. By Immunotherapy Type
11. Middle East and Africa Neoantigen Targeted Therapies Market Outlook
11.1. Market Size & Forecast
11.1.1. By Value
11.2. Market Share & Forecast
11.2.1. By Target Disease Indication
11.2.2. By Neoantigens Type
11.2.3. By Route of Administration
11.2.4. By Immunotherapy Type
11.2.5. By Country
11.3. MEA: Country Analysis
11.3.1. South Africa Neoantigen Targeted Therapies Market Outlook
11.3.1.1. Market Size & Forecast
11.3.1.1.1. By Value
11.3.1.2. Market Share & Forecast
11.3.1.2.1. By Target Disease Indication
11.3.1.2.2. By Neoantigens Type
11.3.1.2.3. By Route of Administration
11.3.1.2.4. By Immunotherapy Type
11.3.2. Saudi Arabia Neoantigen Targeted Therapies Market Outlook
11.3.2.1. Market Size & Forecast
11.3.2.1.1. By Value
11.3.2.2. Market Share & Forecast
11.3.2.2.1. By Target Disease Indication
11.3.2.2.2. By Neoantigens Type
11.3.2.2.3. By Route of Administration
11.3.2.2.4. By Immunotherapy Type
11.3.3. UAE Neoantigen Targeted Therapies Market Outlook
11.3.3.1. Market Size & Forecast
11.3.3.1.1. By Value
11.3.3.2. Market Share & Forecast
11.3.3.2.1. By Target Disease Indication
11.3.3.2.2. By Neoantigens Type
11.3.3.2.3. By Route of Administration
11.3.3.2.4. By Immunotherapy Type
12. Market Dynamics
12.1. Drivers
12.2. Challenges
13. Market Trends & Developments
13.1. Recent Developments
13.2. Product Launches
13.3. Mergers & Acquisitions
14. Global Neoantigen Targeted Therapies Market: SWOT Analysis
15. Porters Five Forces Analysis
15.1. Competition in the Industry
15.2. Potential of New Entrants
15.3. Power of Suppliers
15.4. Power of Customers
15.5. Threat of Substitute Product
16. PESTLE Analysis
17. Competitive Landscape
17.1. BioNtech SE
17.1.1. Business Overview
17.1.2. Company Snapshot
17.1.3. Products & Services
17.1.4. Financials (In case of listed companies)
17.1.5. Recent Developments
17.2. Gritstone Bio, Inc.
17.3. Genocea Biosciences Inc
17.4. Moderna Inc.
17.5. Agenus Inc.
17.6. Immatics N.V.
17.7. Advaxis Inc.
17.8. Precision Biologics
17.9. Gilead Sciences, Inc.
17.10. Cellular Biomedicine Group, Inc.
17.11. Achillies Therapeutics Plc.
17.12. Merck & Co, Inc.
18. Strategic Recommendations
19. About Us & Disclaimer
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security